Articles from: OncLive
Phillip Palmbos, MD, PhD, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder...
-
Phillip Palmbos, MD, PhD, of @umichmedicine, discusses the utilization of adjuvant nivolumab following cystectomy in high-risk, muscle-invasive bladder cancer #blcsm https://t.co/E82kcDkJzu https://t.co/E82kcDkJzu - view on twitter
More coverage:
#blcsm
The addition of zolbetuximab to oxaliplatin, leucovorin, and fluorouracil significantly improved progression-free survival vs fluorouracil alone in patients with Claudin 18.2–positive, HER2-negative, locally advanced...
-
Zolbetuximab + oxaliplatin, leucovorin, & fluorouracil significantly improved PFS vs fluorouracil alone in patients w/ Claudin 18.2+, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. #stomachcancer #oncology https://t.co/0e7RYeNIJX https://t.co/0e7RYeNIJX - view on twitter
Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment...
-
Emerging technologies such as PSMA-PET and magnetic resonance imaging, as well as increasingly refined molecular tests, are strengthening the prostate cancer treatment landscape. @ashleyrossmdphd @NUFeinbergMed #pcsm https://t.co/75MQQkF0rG - view on twitter
More coverage:
#pcsm
The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of mobocertinib for patients with advanced non-small-cell...
-
The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of mobocertinib for advanced NSCLC harboring EGFR exon 20 insertion mutations that has already received platinum-based chemotherapy #lcsm https://t.co/WNIytGvbcL https://t.co/WNIytGvbcL - view on twitter
More coverage:
#lcsm
Tiffany A. Traina, MD, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast...
-
Tiffany A. Traina, MD, of @MSKCancerCenter, discusses the implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer #bcsm https://t.co/Wl02dMSaTy https://t.co/Wl02dMSaTy - view on twitter
More coverage:
#bcsm
Mashup Score:2
OncLiveStandard Induction Evolves in Transplant-Eligible and -Ineligible Multiple Myeloma - 7 hours
Mashup Score:2
Shambavi Richard, MD, discussed key studies that continue to shape the SOC in both the transplant-eligible and -ineligible populations, the role of transplant in...
-
The up-front treatment of patients with multiple myeloma, whether transplant eligible or ineligible, is continuing to change as additional trials and therapies are added to the treatment landscape @IcahnMountSinai #mmsm https://t.co/wm3Qm3Id2t - view on twitter
More coverage:
#mmsm
Mashup Score:1
OncLiveEvolving Treatments Seek to Address Unanswered Questions in Hematologic Malignancies - 8 hours
Mashup Score:1
Novel agents such as momelotinib and pacritinib are expanding the myelofibrosis treatment landscape, and additional research will further define the options available for patients...
-
Dr Schiller highlighted key insights from the meeting, such as novel myelofibrosis agents under investigation, the benefits of CAR T-cell therapy in DLBCL, and the remaining unmet needs that future clinical trials should focus on. @dgsomucla #leusm #lymsm https://t.co/xeMVG0Jzq0 https://t.co/xeMVG0Jzq0 - view on twitter
Raajit K. Rampal, MD, PhD, discusses the investigation of pelabresib with or without ruxolitinib in patients with...
-
WATCH: Raajit K. Rampal, MD, PhD, of @MSKCancerCenter, discusses the investigation of pelabresib with or without ruxolitinib in patients with myelofibrosis. #mpnsm https://t.co/mg8b4etzWQ - view on twitter
More coverage:
#mpnsm
Alexander Babatunde Olawaiye, MD, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and...
-
Alexander Babatunde Olawaiye, MD, of @UPMCHillmanCC, discusses frontline and second-line maintenance in ovarian cancer, the role of surgery in platinum-sensitive disease, and updates in cervical and endometrial cancers #ovca https://t.co/as7YmSQ28N https://t.co/as7YmSQ28N - view on twitter
More coverage:
#ovca
The FDA has granted accelerated approval to mirvetuximab soravtansine-gynx (Elahere) for the treatment of select patients with folate receptor α–positive, platinum-resistant epithelial ovarian, fallopian...
The @US_FDA has granted accelerated approval to mirvetuximab soravtansine for the treatment of select patients with folate receptor α–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. #ovca https://t.co/E1nVwYLtNg - view on twitter